Natural Killer (NK) cells in cancer immunotherapy | Tobias Bald et al. | ResearchPod

Transcript: Natural Killer (NK) cells in cancer immunotherapy

Alex: Natural killer cells may be better understood as orchestrators of the anti-tumor response than as cytotoxic killers. That is the proposal in a Nature Immunology review by Tobias Bald and colleagues, who call it the NK cell-cancer cycle.

Sam: It's a review, so is this demonstrated or a conceptual reframing? And if they don't simply kill on contact, what makes them orchestrators?

Alex: Mostly a framework built on existing evidence. Think of a four-step chain. The cells are recruited to the tumor, they recognize and activate, they deliver cytotoxicity, and then they trigger an adaptive response by alerting dendritic cells. Killing is one link, and the therapeutic value depends on the whole chain running.

Sam: So the failure point is the cycle, not the killing. If a tumor is cold, does the problem usually sit in recruitment or in the later steps?

Alex: Often both. Tumors frequently downregulate the chemokines that drive recruitment, such as CXCL9 and CXCL10. Even when NK cells do infiltrate, physical stromal barriers and inhibitory signals like HLA-G can stall the cycle.

Sam: That would explain why simply adding more cells, the standard adoptive transfer approach, so often disappoints. Without fixing recruitment or the suppressive microenvironment, the infused cells are stranded.

Alex: That is the logic. The field is moving toward engineering cells to bypass those barriers. CAR-NK cells, for instance, can be designed to express specific chemokine receptors so they home into the tumor microenvironment.

Sam: And their allogeneic nature makes them an off-the-shelf option, without the graft-versus-host risk that complicates CAR-T protocols.

Alex: That is the main practical advantage. The review's picture is of NK cells as general contractors who call in air support, rather than soldiers on the front line. The aim is to convert a cold, immunosuppressive tumor into a hot, immunogenic one.

Sam: But NK cells aren't a monolithic population. If CD56bright cells are preferentially recruited to tumors, yet are biased toward cytokine production over cytotoxicity, are we relying on the wrong subset?

Alex: It's a fair challenge. CD56bright cells are the main infiltrators and express less granzyme B and perforin. But in this framework, that is the point: they are a primary source of IFN-gamma and other signals that feed the orchestration step.

Sam: So instead of forcing them toward a cytotoxic CD56dim phenotype, you would engineer the bright cells to survive TGF-beta and adenosine. That sounds appealing, but is it demonstrated, or is it inference from the framework?

It reads as a proposal. What the review supports more directly is that the microenvironment shapes the functional state of these cells. So the strategies are about modulating that environment, through checkpoint blockade or exogenous cytokines like IL-15, to stabilize the orchestrating phenotype. I wouldn't treat the subset question as settled.

Natural Killer (NK) cells in cancer immunotherapy

Tobias Bald, Matthew F Krummel, Mark J Smyth, Kevin C Barry

Jul 20, 2020·5:14·pmc·Original Paper

Natural Killer (NK) cellsCancer ImmunotherapyTumor Microenvironment (TME)Adoptive TransferNK cell-cancer cycleInnate Lymphoid Cells (ILCs)

Listen

5 min

Summary

The Role of NK Cells in Cancer

Natural Killer (NK) cells are innate lymphoid cells that serve as the body's first line of defense against transformed and stressed cells. Unlike T cells, which require specific antigen recognition via the T-cell receptor, NK cells utilize a complex array of germ-line encoded activating and inhibitory receptors to identify and eliminate cancer cells. Beyond their direct cytotoxic function, NK cells act as key regulators of the immune system, shaping the tumor microenvironment (TME) and influencing the adaptive immune response.

The NK Cell-Cancer Cycle

The authors introduce the NK cell-cancer cycle to conceptualize the multi-step process required for effective anti-tumor immunity. This cycle involves: (1) the recruitment of NK cells into the TME, (2) the recognition and activation of NK cells by tumor cells, (3) the direct killing of tumor cells, and (4) the orchestration of adaptive immunity, such as alerting dendritic cells to prime T-cell responses. Each step is governed by a balance of stimulatory and inhibitory signals, which are frequently hijacked by tumors to evade immune surveillance.

Therapeutic Strategies

Recent advances in cancer immunotherapy have focused on exploiting NK cells through several approaches:

Adoptive Transfer: Infusing ex vivo activated NK cells, including CAR-NK cells, which have demonstrated high safety profiles and efficacy in liquid tumors.
Checkpoint Blockade: Targeting inhibitory receptors like NKG2A or KIRs to unleash NK cell activity against tumors that have downregulated MHC-I molecules.
Cytokine Therapy: Using IL-2, IL-15, and IFN-α to boost NK cell survival, proliferation, and effector function.
Engagers: Developing bi-specific or tri-specific killer cell engagers (BiKEs/TriKEs) that physically bridge NK cells to tumor antigens, inducing potent, targeted cytotoxicity.

Why It Matters

While T-cell-based therapies have revolutionized oncology, they often face significant toxicities and resistance mechanisms. NK cells offer a compelling alternative or complementary strategy due to their inherent safety, potential for off-the-shelf use, and unique ability to target tumors that lack MHC expression. Understanding the NK cell-cancer cycle provides a roadmap for developing next-generation immunotherapies that do not just rely on direct killing, but also harness the immunomodulatory power of NK cells to drive durable anti-tumor responses.

Key Terms and Definitions

Missing Self-Recognition — The process by which NK cells identify and destroy target cells that have lost or downregulated MHC-I molecules, which normally inhibit NK cell activation.
CD56dim/CD56bright — The two primary human NK cell subsets, where CD56dim cells are highly cytotoxic and found in blood, while CD56bright cells are immunomodulatory and reside in secondary lymphoid organs.
Trogocytosis — A process where cells exchange membrane fragments and associated proteins, which can lead to the unintended removal of surface receptors targeted by therapeutic antibodies.
CAR-NK Cells — NK cells genetically engineered to express Chimeric Antigen Receptors, redirecting their specificity toward particular tumor-associated antigens.
cDC1 — A subset of conventional dendritic cells specialized in cross-presenting antigens to CD8+ T cells, whose recruitment and survival in the TME are supported by NK cells.

Natural Killer (NK) cells in cancer immunotherapy: Research Paper Podcast